^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RG6919

    i
    Other names: RG6919, YL201, YL-201
    Associations

    News

    Trials
    Company:
    MediLink, Roche
    Drug class:
    Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    2d
    DeLLphi-310: Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P1, N=200, Active, not recruiting, Amgen | Suspended --> Active, not recruiting
    Enrollment closed
    |
    Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle) • RG6919
    8d
    YL201-INT-102-02: A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors (2025-523742-27-00)
    P1/2, N=133, Not yet recruiting, Medilink Therapeutics (Suzhou) Co. Ltd. | N=51 --> 133
    Enrollment change
    |
    Tecentriq (atezolizumab) • RG6919
    15d
    A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=118, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tecentriq (atezolizumab) • RG6919
    23d
    DeLLphi-310: Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P1, N=200, Suspended, Amgen | Recruiting --> Suspended
    Trial suspension
    |
    Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle) • RG6919
    1m
    A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC (clinicaltrials.gov)
    P3, N=440, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan • RG6919
    1m
    YL201-INT-102-02: A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors (2025-523742-27-00)
    P1/2, N=35, Not yet recruiting, Medilink Therapeutics (Suzhou) Co. Ltd.
    New P1/2 trial
    |
    Tecentriq (atezolizumab) • RG6919
    1m
    A Study YL201 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=990, Active, not recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    RG6919
    2ms
    A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=118, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P1/2 trial
    |
    Tecentriq (atezolizumab) • RG6919
    5ms
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. (clinicaltrials.gov)
    P1/2, N=202, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P1/2 trial
    |
    cisplatin • Loqtorzi (toripalimab-tpzi) • RG6919
    5ms
    A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=260, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Yidafan (ivonescimab) • RG6919
    7ms
    A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=260, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P1/2 trial
    |
    Yidafan (ivonescimab) • RG6919
    7ms
    YL201-INT-101-01: A Study of YL201 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=312, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Phase classification: P1 --> P1/2 | N=196 --> 312
    Phase classification • Enrollment change • First-in-human
    |
    Tecentriq (atezolizumab) • RG6919